Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub
Science6 min read

Veradermics' VDPHL01: The Hair Loss Pill Everyone's Searching (2026)

VDPHL01, an extended-release oral minoxidil in late-stage trials, could be the first FDA-approved oral minoxidil for hair loss. What is known so far.

Updated August 30, 2026

Francheska Capistrano, Medical Content Reviewer

Francheska Capistrano, RMT, MPH

Medically reviewed · How we review

Key takeaways

  • VDPHL01 is Veradermics' extended-release oral minoxidil, aiming to become the first FDA-approved oral minoxidil for pattern hair loss - and the first oral hair-loss drug approved for women (oral finasteride is approved only for men).
  • The company reports positive Phase 2/3 results in men (April 2026) and positive early results in women, with major readouts expected in late 2026 and the first half of 2027.
  • It is not approved and not available yet - trial success so far is the company's own reporting, and late-stage trials can still surprise.
  • The active ingredient, minoxidil, is already prescribable today: oral minoxidil is available off-label through hair-loss telehealth providers.

What is VDPHL01?

VDPHL01 is an extended-release oral minoxidil tablet developed by Veradermics, a clinical-stage dermatology company - and the reason searches for it are spiking is its run of trial news. Minoxidil itself is the most familiar name in hair loss, but today's approved products are topical; oral minoxidil is widely prescribed for hair loss only off-label. VDPHL01 is the attempt to change that: run the full FDA trial program and become the first FDA-approved oral minoxidil for pattern hair loss - and the first oral hair-loss drug cleared for women as well as men (today's approved oral option, finasteride, is for men only), a market the company estimates at 50 million men and 30 million women in the US alone.

What have the trials shown so far?

Per the company's own announcements - the honest framing, since peer review and FDA review are still ahead: the Phase 2/3 "302" trial in male pattern hair loss reported positive results in April 2026, described as early, consistent and robust hair growth, and its CEO has claimed faster, stronger growth versus standard minoxidil. On the women's side, an open-label Phase 2 study reported rapid-onset growth, and enrollment is complete in a 556-participant registration-directed Phase 2/3 trial. The catch to keep in view: these are company-reported topline results, and late-stage programs can and do surprise - which is exactly what the remaining readouts are for.

When could it actually be available?

Not soon enough for anyone shedding hair today. The company's stated timeline puts 12-month male data and a confirmatory Phase 3 readout in late 2026, and the women's registration trial readout in the first half of 2027 - and only after successful readouts does an FDA submission and review process begin.

Realistically, that puts any approval well down the road. Treat VDPHL01 as a genuinely promising pipeline story to watch, not a reason to wait: untreated pattern loss progresses, and follicles that spend years miniaturizing are harder to rescue later.

What can you do today instead of waiting?

The ingredient at the center of this story is already prescribable. Oral minoxidil is available off-label right now through licensed telehealth providers - our guide to getting oral minoxidil online covers exactly how, and oral vs topical lays out the trade-offs a prescriber weighs. Combined with finasteride where appropriate, that is the evidence-backed toolkit that exists today - compare the providers we rank, with plans from $24.99/month.

If VDPHL01 clears its remaining trials, it will join that toolkit with an FDA label; until then, the treatment conversation belongs with a licensed provider. This article is general information, not medical advice.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Compare Providers

Related Articles

Science

Iron Deficiency and Hair Loss: The Link, Explained (2026)

Low iron is one of the most common - and most fixable - causes of hair shedding, especially in women. How the link works, the blood test that settles it, and what recovery looks like.

Science

Does Finasteride Really Work for Hair Loss?

What finasteride does, what to realistically expect, how long it takes, who it's for, and the difference between oral and topical finasteride.

Science

Does Creatine Cause Hair Loss? What the Science Actually Says

The creatine-hair loss fear traces back to a single small study. What that study found, what's been shown since, and what actually drives thinning.

Previous

Do Hair Loss Shampoos Actually Work? An Honest Answer (2026)

Next

Best Hims Alternatives for Hair Loss in 2026 (Verified Prices)

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Finasteride - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)
  2. 2.Minoxidil Topical - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)
  3. 3.Hair Loss: Diagnosis and Treatment - American Academy of Dermatology (AAD)
  4. 4.Androgenetic Alopecia (pattern hair loss) - overview - MedlinePlus Genetics, U.S. National Library of Medicine (NIH)